Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of datopotamab deruxtecan in advanced solid tumors
jRCT2080223756Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of datopotamab deruxtecan in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), breast cancer and 8 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Started Dec 2017; status: completed.
02
Drugs
datopotamab deruxtecan
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)breast cancersmall cell lung cancer (SCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080223756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223756.